Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Episode 64

Episode 64

FromBiotech Hangout


Episode 64

FromBiotech Hangout

ratings:
Length:
61 minutes
Released:
Jul 3, 2023
Format:
Podcast episode

Description

On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Tim Opler, Chris Garabedian, Mike Yee and Bruce Booth discuss the week’s industry news including M&A, regulatory, data and more. They highlight the continued M&A streak with Eli Lilly acquiring Dice Therapeutics. They also discuss PhRMA’s lawsuit vs. the U.S. government over IRA Medicare Drug Price Negotiations, following similar suits from Merck & Bristol Myers Squibb. They also talk about several Duchenne news items including Santhera licensing its Duchenne drug to Catalyst and Sarepta’s DMD therapy approval. Additional industry news covered includes the SEC’s case against biotech executives and investors and conflicts of interest with PBMs and FTC’s lawsuit against Amgen. The hosts also discuss what happened to big academic tech transfer deals, Leerink is back, Intercept, Alderya and Arcellx regulatory news, plus Uniqure and Roivant data. *This episode aired on June 23, 2023*
Released:
Jul 3, 2023
Format:
Podcast episode

Titles in the series (72)

A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @DaphneZohar and @JSchimmer_E on Twitter Spaces every Friday at 3pm ET.